Published in AIDS Weekly, August 15th, 2005
The trial involves 150 volunteers and is being conducted at five sites in the United States. This is Bavarian Nordic's second clinical study to evaluate the safety of Imvamune in HIV infected patients and are the only studies evaluating MVA as a safe smallpox vaccine in this population of people, which are contradicted to traditional smallpox vaccines.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.